NCR-300
- Generic Name
- NCR-300
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
Early Phase 1
Not yet recruiting
- Conditions
- Relapsed / Refractory Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Nuwacell Biotechnologies Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05371730
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath